

Attorney Docket No.: INT-0004
Inventors: Mattern et al.
Serial No.: 10/002,653
Filing Date: October 19, 2001
Page 3

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claim 1: (canceled)

Claim 2: (currently amended) The ~~composition of claim 1~~ scaffold or matrix of claim 13 further comprising a silicone layer applied to the collagen and glycosaminoglycan co-precipitate prior to cross-linking.

Claim 3: (currently amended) A terminally sterilized matrix or scaffold comprising the ~~composition of claim 1~~ scaffold or matrix of claim 13 terminally sterilized by electron beam irradiation.

Claim 4: (currently amended) A terminally sterilized matrix or scaffold comprising the ~~composition~~ scaffold or matrix of claim 2 terminally sterilized by electron beam irradiation.

Claim 5: (currently amended) A method for producing the ~~composition of claim 1~~ scaffold or matrix of claim 13 comprising cross-linking the collagen and glycosaminoglycan co-precipitate with glutaraldehyde at a density of cross-linkage which

Attorney Docket No.: INT-0004
Inventors: Mattern et al.
Serial No.: 10/002,653
Filing Date: October 19, 2001
Page 4

stabilizes the ~~composition scaffold or matrix~~ toward electron beam radiation ~~at about 15 to about 80 kGy while retaining~~ ~~characteristics of the composition to function as a~~ so that the matrix or scaffold retains characteristics to function as a structural support for cell and to support tissue ingrowth.

Claim 6: (currently amended) The method of claim 5 wherein cross-linking of the ~~composition~~ collagen and glycosaminoglycan co-precipitate is performed with glutaraldehyde at a concentration greater than 0.25%.

Claim 7: (currently amended) The method of claim 5 wherein the ~~composition~~ collagen and glycosaminoglycan co-precipitate is subjected to two or more glutaraldehyde cross-linking steps.

Claim 8: (original) The method of claim 7 wherein the two or more cross-linking steps are performed with glutaraldehyde at 0.25%.

Claim 9: (currently amended) A method for producing a terminally sterilized matrix or scaffold comprising:

(a) producing a ~~composition of claim 1~~ scaffold or matrix of claim 13;

Attorney Docket No.: INT-0004
Inventors: Mattern et al.
Serial No.: 10/002,653
Filing Date: October 19, 2001
Page 5

(b) sealing the composition in a package; and
(c) exposing the composition in the sealed package to
electron beam radiation.

Claim 10: (canceled)

Claim 11: (original) A terminally sterilized matrix or scaffold
produced in accordance with the method of claim 9.

Claim 12: (original) A method for regenerating dermal or sub-
dermal tissue in a subject comprising applying to or implanting
within the subject the terminally sterilized matrix or scaffold
of claim 3 at or near an excision site of dermal or subdermal
tissue or a site where augmentation of dermal or subdermal tissue
is required.

Claim 13: (currently amended) A ~~composition scaffold or matrix~~
comprising a collagen and glycosaminoglycan ~~co-precipitate~~ cross-
linked with glutaraldehyde at a density of cross-linkage which
stabilizes the ~~composition scaffold or matrix~~ toward electron
beam radiation at about 15 to about 80 kGy while retaining
~~characteristics of the composition to function as a so that the~~

Attorney Docket No.: INT-0004
Inventors: Mattern et al.
Serial No.: 10/002,653
Filing Date: October 19, 2001
Page 6

matrix or scaffold retains characteristics to function as a
structural support for cell and to support tissue ingrowth.